Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007–2023)
Clicks: 3
ID: 314110
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #162 of 214 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background & Aims While surveillance drug resistance mutations (SDRMs) remain essential for monitoring transmitted drug resistance, the clinical impact of transmitted resistance for current first-line regimens has become increasingly important. We aimed to update estimates of transmitted drug resistance (TDR) in Spain and assess its clinical impact over time. Methods Nationwide observational study within the CoRIS cohort. We estimated the prevalence of SDRMs and clinically meaningful resistance (CMR) among ART-naïve individuals with baseline genotypic resistance testing in 2022–2023 and evaluated annual trends in CMR to first-line regimens from 2007 to 2023. CMR was defined as Stanford HIVDB resistance level ≥3. Results In 2022–2023, 1,028 individuals were included; 82.8% were male, 63.2% MSM, and 72.2% subtype B. SDRM prevalence was 14.4% (95% CI 12.2-16.9%), driven mainly by NNRTI-SDRMs, while INSTI-SDRMs remained rare [0.5% (95% CI 0.1-1.5%)]; CMR to recommended first-line regimens was very low. Over 2007–2023, CMR declined markedly, coinciding with adoption of second-generation integrase inhibitors. Rilpivirine-associated resistance mutations were detected in 7.0%, largely due to E138A (4.8%). M184V was detected in 0.8%; 6 of 8 cases occurred in persons with current or prior oral pre-exposure prophylaxis (PrEP), although numbers were small. Conclusions In Spain, TDR remains stable, but its clinical impact on first-line regimens has markedly declined. These findings support Test & Treat strategies and immediate ART initiation with contemporary triple- or dual-drug regimens, while highlighting the need for targeted resistance assessment for rilpivirine-containing regimens and further research on prior PrEP exposure and selected NRTI resistance patterns.
| Reference Key |
openalex_W7161727399
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Paloma Muñoz Báez, Marta Illescas López, Adolfo de Salazar, Iker Falces Romero, Adriana Pinto, Irene Portilla, Mar Masiá, Joaquim Peraire, María Remedios Alemán Valls, Marta Sanchíz, Asunción Iborra, Begoña Baza, Antonio Aguilera, Julián Olalla, Núria Espinosa, JA Iribarren, Laura Gisbert, Arkaitz Imaz, Marta Montero, María Navarro Marcotegui, Ines Suarez-García, Melchor Riera, Maria Jesus Perez Elías, Juan Carlos Galán, Lucio Jesús García Fraile, José Sanz, Sofía Ibarra Ugarte, Enrique Bernal, Blanco, Gemma Navarro, Onofre Martinez, María Isabel Viciana Ramos, Mohamed Omar Mohamen-Balghata, Elena Delgado, Michael M Thompson, Cristina Moreno, Cohorte CoRIS, Ana Fuentes, Féderico García |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag296
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.